333780-75-9

Basic information

• Product Name: 2,3-DIFLUORO-6-IODOBENZOIC ACID
• Synonyms: 2,3-DIFLUORO-6-IODOBENZOIC ACID
• CAS NO: 333780-75-9
• Molecular Formula: C₇H₃F₂IO₂
• Molecular Weight: 284
• Mol File: 333780-75-9.mol

Chemical Properties

• Boiling Point: 298.116°C at 760 mmHg
• Flash Point: 134.096°C
• Appearance: /
• Density: 2.144g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 2,3-DIFLUORO-6-IODOBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIFLUORO-6-IODOBENZOIC ACID(333780-75-9)
• EPA Substance Registry System: 2,3-DIFLUORO-6-IODOBENZOIC ACID(333780-75-9)

Safety Data

• Hazardous Substances Data: 333780-75-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Difluoro-6-iodobenzoic acid is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs. Its unique structure allows for the creation of molecules with specific pharmacological properties, making it a valuable asset in drug design and discovery.
Used in Chemical Industry:
In the chemical industry, 2,3-difluoro-6-iodobenzoic acid is utilized as an intermediate in the production of a range of other chemicals. Its versatility in chemical reactions enables the synthesis of diverse compounds, which can be further processed or used in various applications.
Used in Agrochemical Industry:
2,3-Difluoro-6-iodobenzoic acid has potential applications in the agrochemical field, where it may be employed in the development of new pesticides or other agricultural chemicals. Its chemical properties could be harnessed to create compounds that are effective in controlling pests or improving crop yields.
Used in Material Science:
2,3-Difluoro-6-iodobenzoic acid is used as a building block in the development of new materials, particularly in the realm of organic chemistry. Its incorporation into the molecular structure of these materials can impart unique properties, such as enhanced stability or specific reactivity, which can be beneficial in various applications.

InChI:InChI=1/C7H3F2IO2/c8-3-1-2-4(10)5(6(3)9)7(11)12/h1-2H,(H,11,12)

Upstream product

• 124-38-9 carbon dioxide 
• 64248-58-4 1,2-difluoro-4-iodo-benzene 

Downstream Products

• 1262193-17-8 (2,4,6-trimethylbenzene-1,3,5-triyl)tris(methylene) tris(2,3-difluoro-6-iodobenzoate) 
• 935660-91-6 C₇H₄F₂INO 
• 796967-67-4 4-(4-aminophenyl)-7-fluoro-1H-indazol-3-amine 
• 935660-92-7 2,3-difluoro-6-iodobenzonitrile 

Relevant articles and documents

Syntheses of a radiolabelled CXCR2 antagonist AZD5069 and its major human metabolite

The CXCR2 antagonist AZD5069 has been synthesized in tritium and carbon-14-labelled forms. [3H]AZD5069 was prepared via reductive dehalogenation of an iodinated precursor with tritium gas to provide material with a specific activity of 25.1 Ci/

Measurements of weak halogen bond donor abilities with tridentate anion receptors

The chelate effect of a tridentate receptor is exploited to determine halogen bonding association constants that vary by several orders of magnitude, including interactions of weak donors for which thermodynamic data were not previously available. Free en

Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5- methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor

In our continued efforts to search for potent and novel receptor tyrosine kinase (RTK) inhibitors as potential anticancer agents, we discovered, through a structure-based design, that 3-aminoindazole could serve as an efficient hinge-binding template for kinase inhibitors. By incorporating an N,N′-diaryl urea moiety at the C4-position of 3-aminodazole, a series of RTK inhibitors were generated, which potently inhibited the tyrosine kinase activity of the vascular endothelial growth factor receptor and the platelet-derived growth factor receptor families. A number of compounds with potent oral activity were identified by utilizing an estradiol-induced mouse uterine edema model and an HT1080 human fibrosarcoma xenograft tumor model. In particular, compound 17p (ABT-869) was found to possess favorable pharmacokinetic profiles across different species and display significant tumor growth inhibition in multiple preclinical animal models.